Brii Biosciences Limited released its 2025 Environmental, Social and Governance Report, detailing operational progress in its seventh year.

R&D AND PIPELINE • Research investment reached US$30.29 million, supporting six therapeutic candidates and seven newly authorised patents. • The hepatitis B functional cure programme advanced with Cohort 4 data from the Phase 2b ENSURE study published in Nature Medicine; three Phase 2b trials (ENSURE, ENRICH, ENHANCE) are fully enrolled with read-outs expected in 2H 2026. • The company out-licensed soralimixin for multidrug-resistant infections in Greater China to Joincare Pharmaceutical Group, while continuing to seek partners for HIV assets. • Brii Bio expanded discovery capabilities via new laboratories in Shanghai and Beijing and launched an AI collaboration with OpenBench.

GOVERNANCE AND ETHICS • Independent non-executive directors account for 71 % of the seven-member board, with women holding over 25 % of seats. • No instances of corruption or bribery were reported; directors completed ten hours of compliance training and staff eleven hours. • A supplier code of conduct covering environmental, labour and anti-corruption standards now applies to 241 suppliers (141 in China, 100 overseas).

SOCIAL PERFORMANCE • Workforce totalled 75 employees (58 in China, 17 in the US); 72 % specialise in R&D. • Turnover rate stood at 29.91 %; women held 37.5 % of leadership roles. • Employees completed 3,091 training hours with 100 % coverage. • Brii Bio received Mental Health America’s Platinum Bell Seal for Workplace Mental Health for the second consecutive year.

ENVIRONMENTAL METRICS AND TARGETS • Scope 2 greenhouse-gas emissions were 48.70 tCO₂e; the company aims to reduce emissions annually via a new carbon-management system. • Office electricity consumption fell 10.57 % year on year to 91,784.90 kWh (1,582.50 kWh per employee). • Water use declined 12.00 % to 992.53 m³ (17.11 m³ per employee); 100 % of waste was properly disposed. • Targets focus on further cuts in emissions, energy and water intensity, and increased waste recycling.

OUTLOOK Management reiterated commitment to “patients first, trust, integrity and quality,” with board-level oversight of ESG strategy and an emphasis on aligning incentives with long-term shareholder interests.